Introduction to Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD), also known as maculopathy, is a chronic, progressive disease affecting the central part of the retina, known as the macula. The macula is responsible for sharp central vision, which is essential for reading, recognizing faces, and performing other tasks that require high detail. Damage to the macula in AMD leads to a gradual loss of central vision, significantly reducing patients' quality of life. There are two main forms of AMD: dry (atrophic) and wet (exudative). The dry form is more common and is characterized by thinning of the macula and the formation of drusen—yellowish deposits beneath the retina. The wet form, although less common, causes more severe and rapid vision loss due to the growth of abnormal blood vessels beneath the retina that can leak or bleed.
Optical Coherence Tomography (OCT): The Key to Diagnosis and Monitoring
Modern ophthalmology actively utilizes advanced imaging techniques for accurate diagnosis and monitoring of retinal status. One of the most valuable tools is optical coherence tomography (OCT). This non-invasive method provides detailed cross-sectional images of the retina and choroid, revealing minute structural changes. OCT is indispensable for assessing the thickness of various retinal layers, such as the peripapillary retinal nerve fiber layer (PPRNFL), ganglion cell layer (GCL), as well as choroidal thickness (PPCHT, SFC) and central macular thickness (CMT) [2].
Although some studies demonstrate the use of OCT for monitoring treatment response in other neurological conditions such as migraine [2] or multiple sclerosis [7], its fundamental role in detailed retinal anatomy analysis makes it equally essential for the diagnosis, staging, and progression monitoring of AMD. Regular OCT examinations allow physicians to track disease dynamics, detect signs of transition from the dry to the wet form, and evaluate the efficacy of ongoing therapy, even when dealing with other macular pathologies [6].
The Role of Dietary Supplements in Retinal Health
In the context of macular diseases, the role of nutritional supplements—such as those used in the AREDS/2 (Age-Related Eye Disease Study) trials—is frequently discussed. These supplements typically contain antioxidants (vitamins C and E), zinc, copper, as well as lutein and zeaxanthin, which are important for macular health. However, it is important to note that the efficacy of these supplements may vary depending on the specific disease.
For instance, one study investigated the association between AREDS/2 supplementation and the progression of structural and functional changes in macular telangiectasia type 2 (MacTel), a distinct macular disease different from AMD. The results of this study indicated that AREDS/2 supplementation was not associated with statistically significant differences in disease progression over 24 months in patients with MacTel [1]. This underscores the need for further research and a personalized approach to therapy selection, as even well-known supplements may not have the same effect across different macular pathologies.
Searching for Therapeutic Solutions in Macular Diseases
Treating macular diseases, including AMD, is a complex challenge, and scientists are constantly seeking novel approaches. Although the presented sources do not directly address AMD treatment, they demonstrate active research into therapies for other macular and neurological conditions, highlighting shared challenges and prospects in ophthalmology and neurology.
For example, one case report described the treatment of a juxtafoveal microaneurysm in the setting of paracentral acute middle maculopathy (PAMP), a condition affecting the macula. In this case, a patient with recurrent migraine and a juxtafoveal microaneurysm was empirically prescribed 0.4 mg of nitroglycerin, which resulted in subjective visual improvement and resolution of the lesion on OCT [6]. This example, although related to a different pathology, illustrates the search for unconventional therapeutic solutions and the potential for further research in retinal vascular disorders.
Other studies, while not directly related to AMD, show how novel medications, such as galcanezumab for migraine treatment [3] or immunotherapy for epilepsy [5], improve patients' quality of life, inspiring the development of similarly effective methods for treating eye diseases.
The Future of AMD Treatment: Challenges and Hopes
Despite significant advancements in diagnostics, effective treatment for age-related macular degeneration remains one of the primary goals of modern medicine. The wet form of AMD is successfully treated with anti-VEGF injections, which block the growth of abnormal blood vessels. However, for the dry form of AMD, which is much more common, there are currently no approved therapies to slow down or halt disease progression. Research continues in the areas of gene therapy, cell therapy, neuroprotection, and novel pharmacological agents.
Understanding the mechanisms of AMD development, improving early diagnostic methods using OCT and other technologies, and continuously searching for new therapeutic approaches—as seen in studies of other macular and neurological conditions—offer hope for developing more effective and accessible treatments for millions of people suffering from age-related macular degeneration. The importance of an interdisciplinary approach combining knowledge from ophthalmology, neurology, and pharmacology is becoming increasingly evident to overcome these challenges.
Sources
- [1] Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2. https://pubmed.ncbi.nlm.nih.gov/42479159/
- [2] Optical coherence tomography as a useful tool for monitoring treatment response in migraine: a prospective longitudinal study. https://pubmed.ncbi.nlm.nih.gov/42091745/
- [3] Clinical improvement of photophobia in episodic and chronic migraine with galcanezumab. https://pubmed.ncbi.nlm.nih.gov/42306626/
- [4] Considerations on the use of levetiracetam and lacosamide for the treatment of status epilepticus based on clinical features and prior antiseizure medications. https://pubmed.ncbi.nlm.nih.gov/41928121/
- [5] Successful treatment of epilepsy associated with anti-GAD65 antibody-associated limbic encephalitis despite delayed immunotherapy: a brief report. https://pubmed.ncbi.nlm.nih.gov/42539742/
- [6] A case of juxtafoveal microaneurysm in the setting of paracentral acute middle maculopathy (PAMM): diagnostic and therapeutic challenges. https://pubmed.ncbi.nlm.nih.gov/42109842/
- [7] Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis. https://pubmed.ncbi.nlm.nih.gov/42262609/
- [8] The use of high-efficacy therapy in pediatric multiple sclerosis to prevent long-term disability. https://pubmed.ncbi.nlm.nih.gov/42214041/
Disclaimer: The information provided in this article is for reference purposes only and should not be used for self-diagnosis or self-treatment. Always consult a qualified physician for an accurate diagnosis and an individualized treatment plan.